Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.
暂无分享,去创建一个
Tao Yu | J. Sivak | D. Xirodimas | H. Avet-Loiseau | R. Bremner | J. Corre | P. Monnier | J. Pearson | Dimitris P. Xirodimas | J. Charish | A. Aubry | Tao Yu
[1] T. Maehama,et al. Nucleolar stress: Molecular mechanisms and related human diseases , 2023, Cancer science.
[2] T. Furukawa,et al. Nucleolar Stress Response via Ribosomal Protein L11 Regulates Topoisomerase Inhibitor Sensitivity of P53-Intact Cancers , 2022, International journal of molecular sciences.
[3] S. Goldsmith,et al. Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas , 2022, Current opinion in oncology.
[4] D. Faller,et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML , 2022, Blood advances.
[5] J. Bartek,et al. Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward , 2022, Cancers.
[6] J. Bauman,et al. Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism , 2022, Cell Death & Disease.
[7] A. Carcaboso,et al. Treatment of Retinoblastoma: What Is the Latest and What Is the Future , 2022, Frontiers in Oncology.
[8] A. Santoni,et al. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition , 2021, Cell Death & Disease.
[9] Tao Yu,et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. , 2021, Cancer cell.
[10] C. Rudin,et al. Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas , 2021, Genes & development.
[11] K. Venkatakrishnan,et al. Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial , 2021, Clinical and translational science.
[12] J. Bartek,et al. Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer. , 2020, Trends in cancer.
[13] D. Longley,et al. Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer , 2020, Cell Death Discovery.
[14] Tao Yu,et al. Functional genomics identifies new synergistic therapies for retinoblastoma , 2020, Oncogene.
[15] J. Greenblatt,et al. Nucleolar RNA polymerase II drives ribosome biogenesis , 2020, Nature.
[16] G. Mills,et al. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. , 2020, Cancer cell.
[17] C. Hoogenraad,et al. Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics , 2020, Nature Structural & Molecular Biology.
[18] Tao Yu,et al. Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy , 2020, Cell Death Discovery.
[19] P. Maeder,et al. Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity” , 2019, Progress in Retinal and Eye Research.
[20] K. Venkatakrishnan,et al. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies , 2019, British journal of clinical pharmacology.
[21] Yu Zeng,et al. An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer. , 2019, Oncology letters.
[22] C. Larsson,et al. Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors , 2019, Oncogene.
[23] E. Leich,et al. The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death , 2019, Cell Death & Disease.
[24] T. Graeber,et al. Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. , 2019, Cancer cell.
[25] L. Skalniak,et al. Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists , 2019, Cancers.
[26] T. Hideshima,et al. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity , 2018, Leukemia.
[27] Yi Sun,et al. Protein neddylation and its alterations in human cancers for targeted therapy. , 2018, Cellular signalling.
[28] Michael T. McManus,et al. The Transcriptionally Permissive Chromatin State of Embryonic Stem Cells Is Acutely Tuned to Translational Output. , 2018, Cell stem cell.
[29] Z. Dong,et al. Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin. , 2017, Oncology letters.
[30] J. Yun,et al. Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target , 2017, Cell Death & Disease.
[31] Z. Ni,et al. Properties of STAT1 and IRF1 enhancers and the influence of SNPs , 2017, BMC Molecular Biology.
[32] T. Kohno,et al. GRWD1 negatively regulates p53 via the RPL11–MDM2 pathway and promotes tumorigenesis , 2017, EMBO reports.
[33] Wenyi Wei,et al. Neddylation E2 UBE2F Promotes the Survival of Lung Cancer Cells by Activating CRL5 to Degrade NOXA via the K11 Linkage , 2016, Clinical Cancer Research.
[34] C. Slingluff,et al. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma , 2016, EBioMedicine.
[35] G. Mulligan,et al. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma , 2016, Investigational New Drugs.
[36] A. Lamond,et al. The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway , 2016, Oncogene.
[37] D. Durocher,et al. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities , 2015, Cell.
[38] Meagan E. Sullender,et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.
[39] G. Mulligan,et al. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma , 2015, Clinical Cancer Research.
[40] Jeffrey W. Clark,et al. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.
[41] P. Chen,et al. The novel protective role of P27 in MLN4924-treated gastric cancer cells , 2015, Cell Death and Disease.
[42] F. Zhan,et al. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma , 2015, Clinical Cancer Research.
[43] B. Smith,et al. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors , 2015, Cell Death and Differentiation.
[44] Stephen P. Jackson,et al. Ubiquitylation, neddylation and the DNA damage response , 2015, Open Biology.
[45] M. Peter,et al. Protein neddylation: beyond cullin–RING ligases , 2014, Nature Reviews Molecular Cell Biology.
[46] Yi Sun,et al. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. , 2014, Antioxidants & redox signaling.
[47] Neville E. Sanjana,et al. Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.
[48] Q. Gao,et al. Overactivated neddylation pathway as a therapeutic target in lung cancer. , 2014, Journal of the National Cancer Institute.
[49] G. Tonon,et al. RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS , 2014, Nature Medicine.
[50] E. Lightcap,et al. Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways , 2014, Molecular Cancer Therapeutics.
[51] M. Bohnsack,et al. The 5S RNP Couples p53 Homeostasis to Ribosome Biogenesis and Nucleolar Stress , 2013, Cell reports.
[52] A. Jazaeri,et al. Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924 , 2013, Molecular Cancer Therapeutics.
[53] E. Jonasch,et al. DDX3 regulates DNA damage-induced apoptosis and p53 stabilization. , 2013, Biochimica et biophysica acta.
[54] S. Beausoleil,et al. Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer , 2013, Clinical Cancer Research.
[55] R. Weiss,et al. A novel p21 attenuator which is structurally related to sorafenib , 2013, Cancer biology & therapy.
[56] B. Wasylyk,et al. The NEDD8 conjugation pathway regulates p53 transcriptional activity and head and neck cancer cell sensitivity to ionizing radiation. , 2012, International journal of oncology.
[57] B. Mahata,et al. Recruitment of RPL11 at promoter sites of p53-regulated genes upon nucleolar stress through NEDD8 and in an Mdm2-dependent manner , 2012, Oncogene.
[58] Yi Sun,et al. The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme , 2012, PloS one.
[59] Usha Narayanan,et al. Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. , 2012, Cancer cell.
[60] B. Gallie,et al. Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development , 2012, BMC Cancer.
[61] J. Wrana,et al. Established and New Mouse Models Reveal E2f1 and Cdk2 Dependency of Retinoblastoma and Expose Strategies to Block Tumor Initiation , 2012, Oncogene.
[62] M. Huang,et al. Inhibition of the Nedd8 System Sensitizes Cells to DNA Interstrand Cross-linking Agents , 2012, Molecular Cancer Research.
[63] Z. Darżynkiewicz,et al. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[64] S. Lonial,et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. , 2011, Blood.
[65] E. Cho,et al. Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation , 2011, Cell cycle.
[66] Michael J. Emanuele,et al. Global Identification of Modular Cullin-RING Ligase Substrates , 2011, Cell.
[67] E. Lightcap,et al. Quantitative Proteomic Analysis of Cellular Protein Modulation upon Inhibition of the NEDD8-Activating Enzyme by MLN4924 , 2011, Molecular & Cellular Proteomics.
[68] K. Mimori,et al. Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11 , 2011, Nature Medicine.
[69] Lijun Jia,et al. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. , 2011, Neoplasia.
[70] H. Masumoto,et al. RNA content in the nucleolus alters p53 acetylation via MYBBP1A , 2011, The EMBO journal.
[71] Ya‐Wen Cheng,et al. Reduced p21WAF1/CIP1 via Alteration of p53-DDX3 Pathway Is Associated with Poor Relapse-Free Survival in Early-Stage Human Papillomavirus–Associated Lung Cancer , 2011, Clinical Cancer Research.
[72] Anindya Dutta,et al. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.
[73] M. Dai,et al. Ribosomal Protein L11 Associates with c-Myc at 5 S rRNA and tRNA Genes and Regulates Their Expression* , 2010, The Journal of Biological Chemistry.
[74] Yanping Zhang,et al. Signaling to p53: ribosomal proteins find their way. , 2009, Cancer cell.
[75] Geng-Hung Liu,et al. Regulation of nucleolar signalling to p53 through NEDDylation of L11 , 2009, EMBO reports.
[76] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[77] K. Lam,et al. High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers , 2008, Cancer biology & therapy.
[78] Z. Darżynkiewicz,et al. Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[79] A. Iavarone,et al. The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein , 2008, Nature Cell Biology.
[80] R. Seong,et al. BAF60a Interacts with p53 to Recruit the SWI/SNF Complex* , 2008, Journal of Biological Chemistry.
[81] D. Xirodimas,et al. Ribosomal proteins are targets for the NEDD8 pathway , 2008, EMBO reports.
[82] J. Takahashi,et al. Interpretation of the mouse electroretinogram , 2007, Documenta Ophthalmologica.
[83] Yi Tang,et al. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. , 2006, Molecular cell.
[84] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[85] E. Cho,et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. , 2006, Molecular cell.
[86] P. Raychaudhuri,et al. Cul4A and DDB1 Associate with Skp2 To Target p27Kip1 for Proteolysis Involving the COP9 Signalosome , 2006, Molecular and Cellular Biology.
[87] Z. Darżynkiewicz,et al. Assessment of ATM phosphorylation on Ser‐1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser‐139‐histone H2AX phosphorylation, cell cycle phase, and apoptosis , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[88] M. Takagi,et al. Regulation of p53 Translation and Induction after DNA Damage by Ribosomal Protein L26 and Nucleolin , 2005, Cell.
[89] M. Pagano,et al. Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase* , 2003, Journal of Biological Chemistry.
[90] D. Livingston,et al. MYC recruits the TIP60 histone acetyltransferase complex to chromatin , 2003, EMBO reports.
[91] J. Choe,et al. SWI/SNF Complex Interacts with Tumor Suppressor p53 and Is Necessary for the Activation of p53-mediated Transcription* , 2002, The Journal of Biological Chemistry.
[92] A. Shevchenko,et al. Promotion of NEDD8-CUL1 Conjugate Cleavage by COP9 Signalosome , 2001, Science.
[93] John Calvin Reed,et al. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. , 2000, Cancer research.
[94] Y. Xiong,et al. Human CUL-1, but not other cullin family members, selectively interacts with SKP1 to form a complex with SKP2 and cyclin A. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[95] L. Liu,et al. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. , 1997, Nucleic acids research.
[96] I. Kill. Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component. , 1996, Journal of cell science.
[97] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[98] K. Helin,et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. , 1993, Genes & development.
[99] C. Shields,et al. Retinoblastoma , 1992, Nature Reviews Disease Primers.
[100] P. Sonneveld,et al. Multiple myeloma , 2017, Nature Reviews Disease Primers.
[101] U. Narayanan,et al. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. , 2013, Cancer research.
[102] Hua Li,et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. , 2012, Cancer research.
[103] Joseph Locker,et al. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice , 2010, Nature Genetics.